This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lacey, J. V. Articles by Comstock, G. W. Search for Related Content PubMed PubMed Citation Articles by Lacey, J. V., Jr. Articles by Comstock, G. W.

Null Association between Insulin-like Growth Factors, Insulin-like Growth Factor-binding Proteins, and Prostate Cancer in a Prospective Study

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20852 [J. V. L., A. W. H., C-M. F.], and Department of Epidemiology, The Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland 21205 [S. H., K. J. H., G. W. C.]

	Introduction

Top Introduction Materials and Methods Results Discussion References

 
IGF-1² regulates normal and neoplastic growth in the prostate (1) , and higher serum IGF-1 levels (2) appear to increase prostate cancer risk in epidemiological studies. Other aspects of the IGF axis, such as IGFBP-3 (3) , inconsistently affect risk. Retrospective studies dominate the literature on this topic, and we, therefore, investigated IGF-I and IGFBP-3 in a pilot study from the Clue I population, a prospective cohort study based on the Washington County Serum Bank in Maryland.

We hypothesized that higher serum IGF-1 and lower serum IGFBP-3 are associated with an increased risk of developing prostate cancer.

	Materials and Methods

Top Introduction Materials and Methods Results Discussion References

 
The Washington County Serum Bank began in 1974, when 20,305 consenting adult residents donated blood samples from which serum has been stored at -70°C. This study included 30 cases of histologically confirmed incident prostate cancer (International Classification of Diseases 185) diagnosed between 1976 and 1989 (mean age at diagnosis, 70.6 years; SD, 7.8 years; range, 58–86), selected from a group of 61 cancers from a previous analysis (4) . We identified and matched 60 male controls (2:1) to cases on age (1 year), race (all were Caucasian), and date of blood draw (3 weeks) from the same study.

We shipped (on dry ice) 0.5 ml of serum for each study subject to Diagnostic Systems Laboratories (DSL; Webster, TX), who used ELISA to analyze samples in triplets (one case, two controls) that did not reveal case status. We included four randomly placed triplets of pooled serum for quality control. We measured IGF-1 and IGFBP-3 levels twice for each sample, re-assayed samples if duplicate measures differed by more than 10%, and used the mean value for statistical analysis. We used SAS (SAS Institute Inc., Cary, NC) for logistic regression analysis and adjusted for age at blood draw (50, 51–<60, and 60 years); no other potential confounders (e.g., education, marital status, tobacco use) mattered.

This study had 80% power to detect a relative risk of 3.1 or greater for the highest (versus the lowest) quartile, under the assumption that 25% of controls and 30% of cases would have IGF-1 levels in the highest quartile.

	Results

Top Introduction Materials and Methods Results Discussion References

 
Cases (mean, 119.8 ng/ml; SD, 46.0) and controls (mean, 118.4 ng/ml; SD, 42.8) had nearly identical levels of IGF-1 (Table 1) . IGFBP-3 levels were also similar in cases (mean, 1042.5 ng/ml) and controls (mean, 1022.6 ng/ml). t tests for case-control differences were nonsignificant. Regardless of variable format (e.g., continuous or categorical), neither IGF-1 nor IGFBP-3 was associated with prostate cancer. IGF-1 ORs changed only slightly after adjustment for IGFBP-3 (either continuous or categorical). We also assayed IGF-II and IGFBP-1; levels neither differed in cases versus controls nor were associated with prostate cancer.

	Discussion

Top Introduction Materials and Methods Results Discussion References

The strong association between prostate cancer and elevated IGF-1 levels in a larger study (3) stands out from other studies (2) because of its higher mean and range of IGF-1 levels. If the association is true, higher serum IGF-1 from samples taken years before diagnosis should, in theory, best predict risk (5) because IGF-1 levels fall with age and after prostate cancer diagnosis (1) . Our data do not support that conclusion: we saw no increase in IGF-1 in the sera of men who received a diagnosis of prostate cancer between 6 and 18 years later. In conclusion, although IGFs appear to have a general role in carcinogenesis (1) , the inconsistency of the reported association with prostate cancer warrants further investigation.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom requests for reprints should be addressed, at Environmental Epidemiology Branch, 6120 Executive Boulevard, MSC 7234, Rockville, MD 20852-7234. Phone: (301) 435-3985; Fax: (301) 402-0916; E-mail: jimlacey{at}nih.gov

² The abbreviations used are: IGF, insulin-like growth factor; IGFBP, IGF-binding protein; OR, odds ratio; CI, confidence interval.

Received 3/12/01; revised 5/ 4/01; accepted 6/12/01.

	References

Top Introduction Materials and Methods Results Discussion References

 

1. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur. J. Cancer, 36: 1224-1228, 2000.
2. Cohen P. Serum insulin-like growth factor-I levels and prostate cancer risk—interpreting the evidence. J. Natl. Cancer Inst. (Bethesda), 90: 876-879, 1998.[Free Full Text]
3. Chan J. M., Stampfer M. J., Giovannucci E., Gann P. H., Ma J., Wilkinson P., Hennekens C. H., Pollak M. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science (Wash. DC), 279: 563-566, 1998.[Abstract/Free Full Text]
4. Braun M. M., Helzlsouer K. J., Hollis B. W., Comstock G. W. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control, 6: 235-239, 1995.[Medline]
5. Wolk A., Mantzoros C. S., Andersson S-O., Bergstrom R., Signorello L. B., Lagiou P., Adami H-O., Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer Inst. (Bethesda), 90: 911-915, 1998.[Abstract/Free Full Text]

This article has been cited by other articles:

				A. W. Roddam, N. E. Allen, P. Appleby, T. J. Key, L. Ferrucci, H. B. Carter, E. J. Metter, C. Chen, N. S. Weiss, A. Fitzpatrick, et al. Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies Ann Intern Med, October 7, 2008; 149(7): 461 - 471. [Abstract] [Full Text] [PDF]

				Honors and Awards * Bibliography of Peer-Reviewed Journal Articles Am. J. Epidemiol., October 1, 2008; 168(7): 845 - 854. [Full Text] [PDF]

				M. Anzo, L. J. Cobb, D. L. Hwang, H. Mehta, J. W. Said, S. Yakar, D. LeRoith, and P. Cohen Targeted Deletion of Hepatic Igf1 in TRAMP Mice Leads to Dramatic Alterations in the Circulating Insulin-Like Growth Factor Axis but Does Not Reduce Tumor Progression Cancer Res., May 1, 2008; 68(9): 3342 - 3349. [Abstract] [Full Text] [PDF]

				M. J. Borugian, J. J. Spinelli, Z. Sun, L. N. Kolonel, I. Oakley-Girvan, M. D. Pollak, A. S. Whittemore, A. H. Wu, and R. P. Gallagher Prostate Cancer Risk in Relation to Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3: A Prospective Multiethnic Study Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 252 - 254. [Full Text] [PDF]

				N. E. Allen, T. J. Key, P. N. Appleby, R. C. Travis, A. W. Roddam, S. Rinaldi, L. Egevad, S. Rohrmann, J. Linseisen, T. Pischon, et al. Serum Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3 Concentrations and Prostate Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1121 - 1127. [Abstract] [Full Text] [PDF]

				C. Chen, R. Freeman, L. F. Voigt, A. Fitzpatrick, S. R. Plymate, and N. S. Weiss Prostate Cancer Risk in Relation to Selected Genetic Polymorphisms in Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-3, and Insulin-like Growth Factor-I Receptor Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2461 - 2466. [Abstract] [Full Text] [PDF]

				K. Woodson, J. A. Tangrea, M. Pollak, T. D. Copeland, P. R. Taylor, J. Virtamo, and D. Albanes Serum Insulin-like Growth Factor I: Tumor Marker or Etiologic Factor? A Prospective Study of Prostate Cancer among Finnish Men Cancer Res., July 15, 2003; 63(14): 3991 - 3994. [Abstract] [Full Text] [PDF]

				J. M. Chan, M. J. Stampfer, J. Ma, P. Gann, J. M. Gaziano, M. Pollak, and E. Giovannucci Insulin-Like Growth Factor-I (IGF-I) and IGF Binding Protein-3 as Predictors of Advanced-Stage Prostate Cancer J Natl Cancer Inst, July 17, 2002; 94(14): 1099 - 1106. [Abstract] [Full Text] [PDF]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lacey, J. V. Articles by Comstock, G. W. Search for Related Content PubMed PubMed Citation Articles by Lacey, J. V., Jr. Articles by Comstock, G. W.